Clinical compounds

Prescription-track interventions — off-label gerotherapeutic pharmaceuticals plus injectable peptide therapies. Both pillars share the same gating constraints: physician access, sourcing reliability, and the need for a diagnostic baseline before starting.

Currently take none of these. Met4Min (berberine + chromium + NAC + myo-inositol) is the OTC partial analog of metformin / acarbose — see Supplements.

Pharmaceuticals — off-label gerotherapeutics

Compound	Class	Typical protocol	Mechanism
Rapamycin (Sirolimus)	mTOR inhibitor	5–6 mg once weekly (pulsed)	Inhibits mTOR → autophagy + stem-cell rejuvenation. Considered the flagship pharmacological longevity intervention (extends lifespan across 167 studies / 8 vertebrate species, comparably to strict dietary restriction). Pulsed dosing preserves immune resilience.
Metformin	Biguanide / AMPK activator	~800 mg PM	AMPK activation → simulates caloric restriction; glycemic control; autophagy. Acts on more aging hallmarks than almost any other compound.
SGLT2 inhibitors	SGLT2 class	Often paired with metformin	Blocks renal glucose reabsorption. 24% reduction in premature death over 3 years in a 2026 UCL/LSHTM trial-emulation study on 60,000+ patients. Actively increases telomere length — direct cellular anti-aging. NICE (Feb 2026) proposed alongside metformin as first-line for diabetes.
Acarbose	α-glucosidase inhibitor	~200 mg with carb-heavy meals	Slows complex-carb digestion; blunts postprandial glucose spike.
Trametinib	MEK inhibitor	Research-stage, stacked with rapamycin	Suppresses additional aging pathway; synergistic with rapamycin in preclinical work.

Notes on access

• All are prescription / off-label. UK route is typically a private longevity physician (see Diagnostics for UK clinics).
• Rapamycin + metformin + an SGLT2i is the "modern high-tier" stack the doc identifies.
• Met4Min's berberine covers a sliver of the metformin/acarbose ground OTC — useful as a placeholder while access is sorted, not equivalent.

Injectable peptide therapies

The 2026 peptide landscape clusters into four use-cases: skin/recovery, athletic, "complete glow-up" (GH axis + melanocortin), and nootropic.

Skin & recovery

Peptide	Mechanism	Use
GHK-Cu (systemic)	Copper tripeptide-1 — collagen synthesis + angiogenesis. Topical version is on Skincare; systemic is injectable.	Skin remodelling + wound healing.
BPC-157	Gastric-derived peptide — tissue repair, gut barrier.	Soft-tissue injury recovery, gut healing. Also used in athletic protocols.
TB-500 (Thymosin β-4)	Immune modulation + wound healing.	Athletic injury recovery; stacked with BPC-157.

Complete "glow-up" (GH-axis + pigment)

Peptide	Mechanism	Use
CJC-1295	GHRH analog — growth-hormone secretagogue.	GH-axis stimulation. Stacked with ipamorelin for sustained pulse.
Ipamorelin	Ghrelin-receptor agonist — GH secretagogue.	Synergistic with CJC-1295.
Melanotan II	Melanocortin receptor agonist.	Tanning + UV photoprotection. Cosmetic/aesthetic context.

Nootropic

Peptide	Mechanism	Use
Cerebrolysin	Neurotrophic peptide complex.	Neuroprotection, post-stroke rehab, cognitive support.
Selank	Anxiolytic peptide.	Calm without sedation; cognitive clarity under stress.

Notes on peptide sourcing & administration

• All injectable (subcutaneous typically). Cold-chain dependent.
• Sourcing is the practical bottleneck — research-chemical channels carry purity / contamination risk; clinic-supplied is more expensive but vetted.
• Standard protocols are cyclical, not chronic — e.g. CJC-1295 / ipamorelin 5 days on / 2 off, in 8–12 week blocks.

Gaps & open items

• No diagnostic baseline. Starting any of this without TruAge / lab panels is calibrating in the dark. See Diagnostics — this is the gating action.
• No physician relationship for off-label rx. Pending decision on UK longevity clinic (Span / Hum2n / Nottingham Road).
• Peptide stack is conceptual only — nothing acquired. BPC-157 + GHK-Cu systemic is the lowest-risk starter pair if access opens.